For 250 years Manchester has been putting British innovation firmly on the map. Looking beyond the boundaries of possibility is in Manchester’s DNA. Home to four universities who have a strong track record of working with industry, Manchester provides a climate where innovation can grow and prosper.

Manchester is a key destination for leading global pharmaceutical and MedTech companies, attracting the likes of Kratos Analytical, Waters Corporation and Qiagen. It is also one of the UK’s top three biopharmaceutical clusters and is a member of the European Super League of biomedical clusters.

The city has a well-developed ecosystem that enables companies to gain input and support their innovation in a collaborative network under Health Innovation Manchester, a body formed to speed up the discovery, development and delivery of innovative solutions to help improve the health needs of Greater Manchester’s 2.8m population and further afield.

A DEDICATED INNOVATION DISTRICT
Corridor Manchester is home to a wealth of knowledge intensive organisations operating in the areas of biomedical, pharmaceuticals, precision medicine, clinical trials, eHealth, medical devices and related healthcare. Colocated on the Corridor are two universities, five specialist hospitals, local government, entrepreneurial, global businesses, cultural assets and an Enterprise Zone.

Its facilities are state-of-the-art, which include the internationally renowned Manchester Science Partnerships (MSP) and Citylabs, Manchester’s biomedical centre of excellence. It is also the site of the UK’s multimillion pound ‘smart city’ Internet of Things demonstrator, CityVerve.

A PIONEERING REGION
Manchester will be the only UK city region to integrate health and social care and have devolved control of its £6 billion healthcare budget. This provides unique opportunities for businesses to partner with us to improve patient outcomes, test new integrated delivery models, and adopt new systems and technologies.

As a result of devolution, all related commissioning will take place centrally, giving direct access to one of the largest NHS clusters in the UK. All of this is underpinned by an enhanced digital-health infrastructure that enables world-leading informatics research opportunities.

A recognised leader in digital health, Manchester pioneered the world’s first large-scale, real-world clinical trial, the Salford Lung Study and is one of four Health eResearch Centres that make up the UK’s Farr Institute, England’s only fully e-enabled health trust and Europe’s flagship Connected Health Ecosystem. The ecosystem enables accelerated adoption of digital and Connected Health solutions in health and social care.

MANCHESTER’S LIFE SCIENCES AT A GLANCE

- Home to the National Institute for Health and Clinical Excellence (NICE)
- Home to over 30 NHS organisations
- Home to Europe’s largest clinical academic campus
- Royal Manchester Children’s Hospital, the UK’s largest single site children’s hospital
- Home to 260 biomedical companies
- 157,000 health & social care workforce
- 13,405 life sciences & allied subjects graduates
- Health and Social Care GVA £4BN
Manchester has biomedical research centres in orthopaedics and The Christie, the largest single site cancer treatment and research centre in Europe, treating more than 44,000 patients a year, will be one of two centres in the UK for Proton Beam Cancer Therapy.

The city’s high level of expertise and business opportunities within the sector includes the following enabling capabilities:

**Health Informatics** – with Farr Institute facilities located in Manchester, there are many opportunities to join-up patient health informatics and development of approaches including apps to advance population health and provide a test bed for international investment.

**Precision Medicine** – Manchester’s key therapy area strengths and research capabilities, including cardiovascular and oncology, lend themselves to advancing precision medicine. The Stoller Biomarker Discovery Centre, one of the newest and largest in the world, offer opportunities for industry collaboration, as does the Medical Research Council funded Manchester Molecular Pathology Innovation Centre (MMPathIC).

**Disruptive Medtech** – consequences of a devolved health economy, combined with a clear and collaborative innovation pathway from idea to market access, provide a supportive environment for getting disruptive MedTech innovation to patients in Greater Manchester. There is an existing cluster of MedTech companies and the region also offers opportunities to explore the medical applications of advanced materials such as graphene.

**Key Strengths**

- **Market and test bed** – stable population of 1.5m people with prevalence in chronic disease located within an hour’s drive from Manchester make it the perfect test bed.

- **E-enabled Patient Information** – joined-up healthcare and cutting edge clinical trials and outcomes research underpinned by leading healthcare, coupled with health informatics and electronic data infrastructure.

- **Clinical trial capability** – a unique capability to run industry sponsored clinical and market access/ outcomes studies or related monitoring studies, potentially in real time, as large sections of the population are e-enabled with electronic health records and connected with trial recruitment tools.

**Investors in Manchester:**

Manchester has state-of-the-art life sciences facilities within close proximity to academic, clinical centres of excellence and gateway organisations such as Manchester Institute of Biotechnology, TRUSTECH, Bionow, and GM Academic Health Science Network.

Contact Daniella McCarron, Business Development Executive - Life Sciences, to see how Manchester can support your innovation:

T: +44 (0) 161 237 4470
E: daniella.mccarron@midas.org.uk
Twitter: @MIDAS_LifeSci